ASX Announcement 25 August 2026

FY2026 DELIVERED STRONG FOUNDATIONS FOR GROWTH

Sydney, Australia, Genetic Signatures Limited (ASX: GSS) ("Genetic Signatures" or "the Company") is pleased to announce its results for the year ended 30 June 2026 (FY2026).

HIGHLIGHTS

- Net loss down 30% to $14.0 million (FY2025: $20.1 million) with improved operational performance
- Net operating cash outflow down 37% to $7.8 million (FY2025: $12.3 million)
- $22.1 million in cash and term deposits on 30 June 2026, with no debt
- Revenue of $14.8 million, down 7% on the prior year (FY2025: $15.9 million), reflecting a competitive and price sensitive market and a delayed and muted respiratory testing season in Australia
- Long term supply agreements secured annual recurring revenue
- Organisational restructuring completed, expected to deliver up to $5 million in annualised cost savings from FY2027 onwards
- Ten-year supply agreement signed with Hvidovre Hospital, one of Denmark's leading public hospitals; first commercial order received and testing commenced in August 2026
- CEO Maria Halasz appointed in March 2026; a comprehensive strategic review and growth plan was presented to the market following her first 90 days including stabilising the business, optimising resources and scaling into opportunities for sustainable growth

Operational overview

Sales of the 3base® *EasyScreen*™ Detection Kits and systems in FY2026 resulted in $14.8 million in revenue, a decrease of 7% on the prior year (FY2025: $15.9 million). The result reflects a competitive and price sensitive trading environment together with a delayed and muted respiratory testing season in Australia. Long term supply agreements have been signed with major customers during the reporting period securing the Company's recurring revenue with built in annual growth rates. Revenue from new accounts included instrument supply under the ten-year supply agreement with Hvidovre Hospital in Denmark.

Net loss for FY2026 was down by 30% to $14.0 million (FY2025: $20.1 million), including a $2.1 million impairment expense recognised principally against property, plant and equipment no longer in use (FY2025: $7.0 million, principally the impairment of previously capitalised product development intangibles).

Net operating cash outflows improved by 37% to $7.8 million (FY2025: $12.3 million), which included $0.8 million of one-off redundancy payments relating to the organisational restructuring completed during the year.

Gross margin on materials was 43% for FY2026, down from 55% in the prior year, reflecting an increased inventory obsolescence provision including $2.0 million of inventory write-downs and obsolescence provision charges recognised in cost of materials, pricing adjustments, higher raw material input costs, recipe changes and capitalisation review of production overheads.

Strategic and operational transformation

Following her appointment in March 2026, CEO Maria Halasz led a comprehensive strategic review across every part of the business that resulted in a growth strategy presented to investors in June 2026. The review set a clear direction guided by three principles:

- **Stabilise** the business through resource stewardship;
- **Optimise** delivery through focused execution; and
- **Scale** through focus on profitable market opportunities

The organisational restructuring announced in March 2026 was completed during the fourth quarter, resulting in 30 positions made redundant across five divisions, alongside the transition of certain product development activities to specialist contract research organisations. The restructuring is expected to deliver estimated annualised cost savings of up to $5 million from FY2027, with one-off redundancy costs of $0.8 million settled during the year. The net P/L effect of the restructure was $0.21 million in FY2026 after taking into account leave and bonus provisions.

Impairment and new strategic direction for automation

As part of the strategic review of the organisation, the Company completed an assessment of its fixed asset base, including instruments held for placement at customer sites and equipment associated with the paused platform development program. An impairment expense of $2.1 million was recognised during the year, principally against property, plant and equipment identified as no longer in use.

The Company's program for the development of a customised liquid handling instrument has been paused. Development of an alternative automation solution is well underway with established manufacturers. The Company is also broadening its respiratory and enteric pathogen detection portfolios, including the outsourced development of a new enteric pathogen detection product, to extend the reach of its proprietary 3base® technology and increase revenue.

Commercial update

Australia

Australian revenue for FY2026 totalled $13.2 million (FY2025: $14.4 million), reflecting the competitive and price sensitive environment the Company continues to operate in, in addition to a delayed respiratory testing season. Australia remains the foundation of the business, with the Company's multiplex *EasyScreen*™ assays deeply embedded in laboratory workflows and subject to long term supply agreements.

EMEA

EMEA revenue for FY2026 was $1.4 million (FY2025: $1.5 million), representing 9.4% of total revenue, supported by new account onboarding. Following the signing in April 2026 of the ten-year supply agreement with Hvidovre Hospital in Denmark, equipment order was installed in May 2026. The first reagent order was received in August and commercial testing has since commenced following successful completion of in situ validation and verification studies. Together with the results laboratories are achieving with *EasyScreen*™ in the United Kingdom, this demonstrates growing momentum for the Company's pan-enteric approach across Europe in the infection prevention and verification space. The Company continues to build distribution partnership opportunities in the region.

USA

As part of a comprehensive organisational review, the Company commenced resetting its United States business by exploring alternative approaches for market access before committing further resources. The Company has booked sales in the USA (FY2026: $0.2 million, FY2025: nil), however, these are not expected to grow materially until such time as the new market access strategy is implemented. The Company remains confident in the long-term potential of its differentiated portfolio.

Capital management

On 30 June 2026, GSS held $22.1 million in cash and term deposits (30 June 2025: $31.3 million) and remains debt-free. Working capital reduced during the year, with inventories decreasing to $6.2 million (FY2025: $9.1 million) following a focused program of consuming existing stock, completing the annual obsolescence review and tighter purchasing discipline. As of the date of this report available cash and equivalents stand at $21.3 million.

Leadership changes

Ms Allison Rossiter, CEO, and Mr Karl Pechmann, CFO, resigned effective 28 February 2026 and 30 January 2026 respectively. Ms Anne Lockwood was appointed Interim Managing Director from 2 March 2026 to support the CEO transition as Ms Maria Halasz was appointed Chief Executive Officer and commenced with the Company on 2 March 2026.

Effective 8 May 2026, Ms Lockwood concluded her role as Interim Managing Director and returned to her position as a Non-Executive Director and Chair of the Audit Committee, and Dr Neil Gunn resigned as a Non-Executive Director. The Company acknowledges Dr Gunn's years of service and is thankful for his contribution to the business.

Subsequent events

On 2 July 2026, BCAL Diagnostics Limited announced that it had acquired a shareholding of approximately 10.2% in the Company (23,173,644 ordinary shares).

Dr Susanne Pedersen will step down from her role as Chief Technology Officer, effective 20 October 2026, and is expected to transition into a strategic consulting role to provide targeted support for the Company's technology and product development programs.

The installation and validation of the Company's *EasyScreen*™ Pan-Enteric assay at Hvidovre Hospital, Denmark, has been successfully completed. The order for the first quarter supply of tests was delivered on 18 August 2026, and commercial testing is now underway.

The Board continues to actively pursue partnership opportunities that offer strong strategic fit with the Company's business to accelerate scaling and deliver increased value for shareholders.

No other matter or circumstance has arisen since 30 June 2026 that has significantly affected, or may significantly affect, the Company's operations or state of affairs.

Outlook

The Company enters FY2027 with new long-term customer contracts, a leaner cost base delivering estimated annualised savings of up to $5 million, and a clear strategic direction to optimise resources and scale the business. Key goals over the next twelve months include:

- Continuing to service Australian customers through existing long-term contracts and new product delivery and pursuing the Company's Asia Pacific market access strategy, including opportunities in hospitals and independent laboratories
- Servicing the existing EMEA customers, including the newly secured Hvidovre Hospital contract in Denmark, and growing the EMEA customer base through distributors, leveraging the growing need for infection prevention and control in hospitals
- Resetting the US market access strategy, incorporating previous learnings and current market trends including the assessment of launching the Company's products as laboratory developed tests
- Broadening the *EasyScreen*™ pathogen detection assay portfolios to improve the Company's position as a differentiated molecular diagnostics business and to increase product revenue
- Evaluating instrument partnerships with third-party manufacturers to secure long term supply of automation equipment delivering cutting edge robotics to the Company's customers
- Actively pursuing strategic partnerships that offer business synergies and opportunities for scaling and building shareholder value

Forward-looking statements

This announcement contains forward-looking statements, including statements regarding expected cost savings, anticipated customer orders, market access plans and future financial performance. Forward-looking statements are based on the Company's current expectations and assumptions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. Actual results may differ materially from those expressed or implied. The Company does not undertake to update any forward-looking statement, except as required by law.

– END –

Announcement authorised by Genetic Signatures' Board of Directors.

For further information, see our website (www.geneticsignatures.com) or contact us:

Maria Halasz
Chief Executive Officer
maria.halasz@geneticsignatures.com
T: +61 (0)2 9870 7580

About Genetic Signatures Limited:

Genetic Signatures is a specialist molecular diagnostics company focused on the development and commercialisation of its proprietary platform technology, 3base®. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the EasyScreen™ brand. Genetic Signatures' proprietary 3base® platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' current target markets are major hospital and pathology laboratories undertaking infectious disease screening.